These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33201438)

  • 1. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
    Halpin DMG; Criner GJ; Dransfield MT; Han MK; Hartley B; Harvey C; Jones CE; Kato M; Lange P; Lettis S; Lomas DA; Martinez FJ; Martin N; Singh D; Wise R; Zheng J; Lipson DA
    Pulm Ther; 2021 Jun; 7(1):101-118. PubMed ID: 33201438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
    Bourdin A; Criner G; Devouassoux G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kalhan R; Lange P; Lettis S; Lipson DA; Lomas DA; Echave-Sustaeta María-Tomé JM; Martin N; Martinez FJ; Quasny H; Sail L; Siler TM; Singh D; Thomashow B; Watz H; Wise R; Hanania NA
    Chronic Obstr Pulm Dis; 2021 Jan; 8(1):76-90. PubMed ID: 33156982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
    Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
    Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial.
    Thomashow B; Stiegler M; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Lange P; Martinez FJ; Midwinter D; Singh D; Tabberer M; Wise RA; Lipson DA; Jones P
    Chronic Obstr Pulm Dis; 2022 Jan; 9(1):68-79. PubMed ID: 34972260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
    Thompson PJ; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Lipson DA; Maghzal GJ; Martinez FJ; Midwinter D; Singh D; Tombs L; Wise RA
    Respirology; 2022 Dec; 27(12):1034-1044. PubMed ID: 35970518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
    Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
    Dransfield MT; Crim C; Criner GJ; Day NC; Halpin DMG; Han MK; Jones CE; Kilbride S; LaFon D; Lipson DA; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Lange P
    Ann Am Thorac Soc; 2021 May; 18(5):788-798. PubMed ID: 33108212
    [No Abstract]   [Full Text] [Related]  

  • 14. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
    Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
    Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
    Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
    Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
    Han MK; Criner GJ; Dransfield MT; Halpin DMG; Jones CE; Kilbride S; Lange P; Lettis S; Lipson DA; Lomas DA; Martin N; Wise RA; Singh D; Martinez FJ
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1237-1243. PubMed ID: 32584168
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
    Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
    Tabberer M; Jones CE; Kilbride S; Halpin DMG; Lomas DA; Pascoe S; Singh D; Wise RA; Criner GJ; Lange P; Dransfield MT; Han MK; Martinez FJ; Kaisermann MC; Lipson DA
    Adv Ther; 2020 Sep; 37(9):3775-3790. PubMed ID: 32647911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.